NeuroOne Medical Tech (NASDAQ:NMTC) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 63.64 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $2.741 million which beat the analyst consensus estimate of $2.470 million by 10.97 percent. This is a 906.67 percent increase over sales of $272.284 thousand the same period last year.